Fusen Pharmaceutical Company Limited

1652

KYG370981030

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:08:12 14/06/2024 BST			5-day change	1st Jan Change
1.17 ^HKD	0.00%		-0.85%	-14.60%

05-31	Chinese Regulators Accept Fusen Pharmaceutical’s Drug Application	MT
04-04	Fusen Pharmaceutical's Type 2 Diabetes Drug Application Accepted by Chinese Regulator	MT

Fusen Pharmaceutical Company Limited Announces Executive Changes, with Effect from 29 January 2021

January 29, 2021 at 01:36 pm

The board of the directors of Fusen Pharmaceutical Company Limited announced that Mr. Pang Wai Ching has tendered his resignation as the company secretary of the Company with effect from 29 January 2021 Following the resignation of Mr. Pang, announced that Mr. Wong Tik Man has been appointed as the Company Secretary and the Authorised Representative with effect from 29 January 2021.

Latest news about Fusen Pharmaceutical Company Limited

Chinese Regulators Accept Fusen Pharmaceutical’s Drug Application	05-31	MT
Fusen Pharmaceutical's Type 2 Diabetes Drug Application Accepted by Chinese Regulator	04-04	MT
Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I)	04-03	CI
Fusen Pharmaceutical Posts Higher Loss in 2023	04-01	MT
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Year Ended 31 December 2023	03-15	CI
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023	29/08/23	CI
Fusen Pharmaceutical Forecasts Return to Profitability in H1	11/08/23	MT
Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023	10/08/23	CI
Fusen Pharmaceutical Company Limited commences an Equity Buyback Plan for 75,843,900 shares, representing 10% of its issued share capital, under the authorization approved on May 30, 2023.	31/05/23	CI
Fusen Pharmaceutical Company Limited's Equity Buyback announced on June 2, 2022, has expired.	29/05/23	CI
Tranche Update on Fusen Pharmaceutical Company Limited's Equity Buyback Plan announced on June 2, 2022.	28/03/23	CI
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	28/03/23	CI
Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Year Ended 31 December 2022	28/03/23	CI
Fusen Pharmaceutical to Swing to Loss in 2022	14/03/23	MT
Fusen Pharmaceutical Company Limited Provides Earnings Guidance for the Year Ended 31 December 2022	13/03/23	CI
Fusen Pharmaceutical, Directors Hit with Disciplinary Action for Disclosure Breaches	04/01/23	MT
Fusen Pharmaceutical Company Limited Announces Change of Principal Place of Business in Hong Kong	15/12/22	CI
Tranche Update on Fusen Pharmaceutical Company Limited's Equity Buyback Plan announced on June 2, 2022.	29/08/22	CI
Fusen Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022	29/08/22	CI
Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Six Months Ended June 30, 2022	29/08/22	CI
Fusen Pharmaceutical Forecasts Swing to Loss in January-June Results	22/08/22	MT
Fusen Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022	19/08/22	CI
Fusen Pharmaceutical Company Limited, as Distributor, and Taumedika Srl., an Independent Third Party, as Supplier, Entered into Distribution Agreement	18/07/22	CI
Fusen Pharmaceutical Company Limited commences an Equity Buyback Plan for 76,993,400 shares, representing 10% of its issued share capital, under the authorization approved on May 31, 2022.	02/06/22	CI

Chart Fusen Pharmaceutical Company Limited

Duration

Period

Chart Fusen Pharmaceutical Company Limited

More charts

Company Profile

Fusen Pharmaceutical Co Ltd is a China-based company principally engaged in the provision of Shuanghuanglian series cold medicines. The Company is mainly engaged in research, development, production and sales of Chinese patent drugs and western medicine products for the treatment of cold and fever, cardiovascular diseases and anemia. The Company's main products include small volume injections, oral liquids, tablets, capsules and granules. The Company distributes its products mainly in domestic market.

Sector

Pharmaceuticals

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
FUSEN PHARMACEUTICAL COMPANY LIMITED	-14.60%	111M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.37%	43.54B
OTSUKA HOLDINGS CO., LTD.	+19.44%	21.78B
SANDOZ GROUP AG	+17.85%	15.38B
CIPLA LIMITED	+25.55%	15.12B
ZYDUS LIFESCIENCES LIMITED	+60.99%	13.36B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-15.02%	6.38B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.17%	5.32B

Generic Pharmaceuticals